RSV: On the verge of change

After decades of failed attempts, the respiratory syncytial virus (RSV) treatment and vaccine landscape is on the verge of profound change.

 

RSV: On the verge of changeSeveral pharmaceutical companies have an RSV vaccine or preventative treatment in late-stage clinical trials – demonstrating highly promising results – and are racing to become the first to market.

In this short article, we highlight some of the key developments in this area, potential knowledge gaps and considerations for the future.

Download the full paper

Download

The author(s)

Related news

  • KEYS: Our World in Motion
    E mobility Events replay

    [Webinar] KEYS: Our World in Motion

    At our next KEYS webinar, we’ll be launching the inaugural Ipsos Mobility Report.
  • [Webinar] Real evidence from real experiences: Patient Centric Evidence
    Healthcare Webinar

    [Webinar] Real evidence from real experiences: Patient Centric Evidence

    Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
  • Battle For Attention - KEYS Webinar from Ipsos
    Communications Events replay

    [Webinar] KEYS: Battle For Attention

    In today’s hyper-fragmented landscape, communicating using short-form content and social media platforms is an essential part of our toolkit. But are they better suited to short-term engagement rather than long-term brand building? And what does genuinely innovative and creative advertising look like these days?